Compare

Nanobiotix/$NBTX

1D1W1M3M6MYTD1Y5YMAX

About Nanobiotix

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Ticker
$NBTX
Sector
Health
Primary listing
NASDAQ
Employees
100
Headquarters
Paris, France
Website
www.nanobiotix.com

Nanobiotix Metrics

BasicAdvanced
$1.3B
-
-$1.22
0.57
-

What the Analysts think about Nanobiotix

Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Analyst projections of the future price of Nanobiotix stock.

Bulls say / Bears say

An MD Anderson-sponsored Phase 1 study in recurrent lung cancer reported 79% one-year control of treated areas and 70% one-year overall survival among 24 patients. No severe events were attributed to NBTXR3 or its injection, making this an encouraging early signal for re-irradiation. (BioSpace)
In the Phase 2 CONVERGE study, seven patients who completed the full treatment regimen had an 85.7% overall response rate and a 57.1% complete response rate. These early results suggest potential activity in stage III lung cancer. (Nanobiotix)
Nanobiotix reported €110.9 million in cash at 30 June 2026 and expects it to fund operations into 2029 under its current plan. That gives the company more time to advance its clinical programmes before needing further funding. (StockTitan)
In the 24-patient recurrent lung study, 8% of patients had a Grade 5 radiotherapy-related adverse event. Although these events were not attributed to NBTXR3, they underline the safety risks of combining it with re-irradiation. (StockTitan)
NBTXR3 remains investigational, and its pivotal NANORAY-312 head-and-neck cancer trial has yet to deliver final results; Nanobiotix expects the readout in the first half of 2027. Failure to show a benefit would threaten the lead programme’s prospects. (Yahoo Finance)
The widely cited $2.6 billion value of the J&J deal is potential, not guaranteed revenue: payments depend on future development, regulatory and sales milestones. Nanobiotix therefore relies heavily on its partner’s progress to realise the commercial upside. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2026.

Nanobiotix Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Nanobiotix Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.